Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + anti-PD-(L)1 + tegafur-based chemotherapy in second-line advanced pancreatic cancer
ChiCTR2200058431Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and tegafur in pancreatic cancer (PC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: objective response rate and safety. Started Jun 2022; status: recruiting.
02
Drugs
tucidinostattegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2200058431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058431.